title: Abnormal Corneal Lesions Induced by Trastuzumab Emtansine: An Antibody-Drug Conjugate for Breast Cancer.
abstract: OBJECTIVE
  To report a case of atypical corneal lesions presumably induced by trastuzumab emtansine, an antibody-drug conjugate that is designed to selectively deliver cytotoxic agents to human epidermal growth factor receptor 2 (HER2)-positive breast cancer cells.
  
  
  METHODS
  A 64-year-old Japanese woman developed bilateral corneal epithelial abnormalities that originated from the limbus. The corneal lesions covered the superior area in the right eye and both superior and inferior areas including the visual axis in the left eye. The patient had advanced ductal carcinoma of the left breast and had been receiving anticancer treatment with trastuzumab emtansine for 15 months. After switching the chemotherapy from trastuzumab emtansine monotherapy to the combination of docetaxel, trastuzumab, and pertuzumab, the abnormal corneal lesions showed gradual improvement.
  
  
  CONCLUSIONS
  As corneal epithelial cells express human epidermal growth factor receptor 2 under normal conditions, such cells may also be targeted by trastuzumab emtansine and lead to corneal epithelial lesions.
authors.affiliation: *Department of Ophthalmology, Kyorin University School of Medicine, Mitaka, Japan; †Department of Ophthalmology, Kawasaki Municipal Ida Hospital, Kawasaki, Japan; and ‡Department of Breast Surgery, Kyorin University School of Medicine, Mitaka, Japan.
authors.forename: Mayuko
authors.initials: M
authors.lastname: Tsuda
authors.forename: Yoji
authors.initials: Y
authors.lastname: Takano
authors.forename: Chika
authors.initials: C
authors.lastname: Shigeyasu
authors.forename: Shigeru
authors.initials: S
authors.lastname: Imoto
authors.forename: Masakazu
authors.initials: M
authors.lastname: Yamada
mesh_terms: D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy*; D003316:Corneal Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D057915:Drug Substitution; D019573:Epithelium, Corneal / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D008453:Maytansine / Q000009:adverse effects / Q000031:analogs & derivatives*; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D000068878:Trastuzumab; D014792:Visual Acuity
chemical_list: D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D008453:Maytansine; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human